Younis, Sumera Y.
Barnier-Quer, Christophe
Heuking, Simon
Sommandas, Vinod
Brunner, Livia
vd.Werff, Nicole
Dubois, Patrice
Friede, Martin
Kocken, Clemens
Collin, Nicolas
Remarque, Ed
Funding for this research was provided by:
EU-FP7 PHARVAT (FP7-HEALTH-2007- 223226)
EU-FP7 project TRANSVAC (EU-FP7 project TRANSVACFP7-INFRASTRUCTURES-2008-228403)
Article History
Received: 24 May 2017
Accepted: 24 January 2018
First Online: 31 January 2018
Authors’ information
: SYY, VS, NW, CK and ER are employees of Biomedical Primate Research Centre, The Netherlands. CB, SH, LB and NC are employees of the Vaccine Formulation Laboratory, University of Lausanne, Switzerland. PD is self-employed. MF is an employee of WHO, Switzerland.
: All animal work was performed under the guidelines of Biomedical Primate Research Centre (BPRC) which uses protocols conforming to European animal welfare regulations. The independent ethics committee at BPRC, constituted according to Dutch law on animal experiments, approved the study protocol (number DEC 658) prior to start of the experiment.
: Not Applicable.
: Authors declare no competing financial interests. SYY, VS, NW, CK and ER are employees of Biomedical Primate Research Centre, The Netherlands. CB, SH, LB and NC are employees of the Vaccine Formulation Laboratory, University of Lausanne, Switzerland. PD is self-employed. MF is an employee of WHO, Switzerland.